Gonorrhea treatment is hitting a wall. Ciprofloxacin, an antibiotic largely abandoned by clinicians in the early 2000s, could return to the frontline for a majority of cases if new resistance-guided testing becomes standard. This approach targets a specific gene mutation to determine susceptibility, potentially sparing ceftriaxone as resistance to that drug climbs worldwide. The strategy aims to prevent a scenario where no effective treatment remains for a common sexually transmitted infection.
The Shrinking Toolbox for Treatment
Lao-Tzu Allan-Blitz, MD, MPH, assistant clinical professor of medicine at the David Geffen School of Medicine at UCLA, describes the current situation as a crisis. Neisseria gonorrhoeae has developed resistance to nearly every antibiotic used against it over the past several decades. The consequences of treatment failure are severe, including an increased risk for acquiring HIV, pelvic inflammatory disease among women, infertility, and neonatal blindness. The financial toll is also significant, with estimated lifetime costs reaching hundreds of millions of dollars for infected individuals.
Clinicians dropped ciprofloxacin from their protocols once resistance rates reached 5% in the early 2000s. They shifted to ceftriaxone, which remains the current standard of care. However, resistance to ceftriaxone now exceeds 25% in some regions outside the United States. This rise raises concern about a treatment gap with no clear successor drug available to replace it.
Read Also: Peggy Lillis Foundation Honors C Diff Advocates
Allan-Blitz notes that roughly 60% of N. gonorrhoeae strains circulating in the US remain susceptible to ciprofloxacin. This statistic forms the basis for the proposed return of the drug. If clinicians can reliably identify which patients have susceptible strains, they can prescribe ciprofloxacin safely, preserving ceftriaxone for cases that truly require it.
Targeting a Single Gene Mutation
The core of this strategy involves identifying a single mutation in codon 91 of the gyrA gene. Allan-Blitz states that this specific mutation is 98% sensitive and 98% specific for predicting ciprofloxacin resistance. Rapid molecular assays targeting this location have been developed and are now commercially available in the United States and other countries. These tests allow clinicians to determine the gonorrhea genotype within a number of hours up to a day.
For symptomatic patients, immediate treatment is required. However, more than half of infections, perhaps 60%, are asymptomatic. In these cases, there is a window of time where a clinician can collect a swab or urine sample and send it to the laboratory. Results may take a day to return. If positive results are reflexed to a gyrA genotyping assay, clinicians can receive the gonorrhea status and the genotype results simultaneously. This workflow enables targeted therapy rather than blanket prescribing.
This resistance-guided therapy model is already a standard of care for Helicobacter pylori and is used for methicillin-resistant Staphylococcus aureus treatment. Applying the same logic to gonorrhea represents a pragmatic step forward. For patients in regions where ceftriaxone resistance is rising, this diagnostic precision offers a practical path to effective treatment without waiting for new antibiotics to be developed and approved.
Read Also: Tattoos Offer Unexpected Relief for Anxiety Sufferers
Expanding the Diagnostic Panel
Allan-Blitz’s lab has not stopped at ciprofloxacin. The team has identified genetic markers that predict susceptibility to cefixime, penicillin, and doxycycline. The goal is to build a full panel of resistance-guided diagnostics. This broader toolkit would allow for more personalized treatment plans based on the specific genetic profile of the infection. Scaling this approach globally is critical, as resistant strains move quickly across borders. Ceftriaxone-resistant cases have already been imported into the US from regions with high resistance prevalence.
Insurance reimbursement remains a separate hurdle for widespread adoption. Allan-Blitz pointed to a recent CPT code approval for a Mycoplasma genitalium resistance assay as a potential precedent. “CMS just set a reimbursement rate for that CPT code, and we’re applying the same sort of logic to the gyrA codon 91 assay,” he said. “We don’t have that code yet, so it’s not in my hand, but once we have it in hand, I’m hoping that FDA-cleared tests, CPT code for reimbursement, commercially available assays, and high burden of need, we will start to really move the needle.”
The path forward involves aligning diagnostic capabilities with reimbursement structures. Without a clear code for billing, the financial barrier may limit access to these tests. The existing framework for other resistance assays provides a model, but the specific implementation for gyrA codon 91 is still pending. Clinicians are watching for these administrative developments closely, as they determine whether the clinical potential of rapid genotyping can translate into routine practice.
Leave a Reply